Pemetrexed for the first-line treatment of non-small-cell lung cancer

  • Technology appraisal guidance
  • TA181
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1

Pemetrexed in combination with cisplatin is recommended as an option for the first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma.

1.2

People who are currently being treated with pemetrexed for NSCLC but who do not meet the criteria in 1.1 should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.